Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluconazole vs Nystatin for Oropharyngeal Candidiasis in AIDS
NCT00002112Phase 3Completed
- Sponsor
- Pfizer
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluconazole in oropharyngeal candidiasis (OPC) (2 arms), sponsored by Pfizer. Primary endpoint: Clinical Cure Rate at 14 days. Status: completed.
02
Drugs
fluconazole
03
Conditions
oropharyngeal candidiasis (OPC)
Beyond the preview
Go deeper on NCT00002112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002112.